Privia Health initiated with a Buy at Needham

Needham analyst Matthew Shea initiated coverage of Privia Health (PRVA) with a Buy rating and $25 price target Privia is “one of the most diverse VBC enablers among companies in our deep dive,” working closely with providers and payors to facilitate transitions to value-based care across population types, the analyst tells investors. Privia’s lower exposure to capitated risk positions them as one of the best public VBC operators headed into 2025, the analyst added.